Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody engineering for therapeutics.

Leonard Presta1

  • 1Department of Protein and Antibody Technology, DNAX Inc, 901 California Avenue, Palo Alto, CA 94304-1104, USA. leonard.presta@dnax.org

Current Opinion in Structural Biology
|September 2, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.

Molecular cancer therapeutics·2023
Same author

Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Evolving an anti-toxin antibody.

Nature biotechnology·2007
Same author

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

The Journal of clinical investigation·2006
Same author

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Cancer immunology, immunotherapy : CII·2005
Same author

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.

Molecular cancer therapeutics·2005

Engineered antibodies show promise in clinical trials, with new effector functions like reactive oxygen species generation and expanded use of immunoglobulin A antibodies for therapeutic applications.

Area of Science:

  • Biotechnology
  • Immunology
  • Pharmacology

Background:

  • Antibodies are increasingly accepted as therapeutics.
  • Engineered antibody variants aim to enhance efficacy and target specificity.
  • Current research explores novel antibody effector functions and formats.

Purpose of the Study:

  • To review advancements in engineered antibody therapeutics.
  • To highlight emerging effector functions, such as reactive oxygen species generation.
  • To discuss the expansion of antibody therapeutics beyond immunoglobulin G.

Main Methods:

  • In vitro investigations of engineered antibody functions.
  • Analysis of antibody formats including immunoglobulin G and immunoglobulin A.
  • Review of preclinical and clinical trial data for antibody therapeutics.

Related Experiment Videos

Main Results:

  • Engineered antibodies demonstrate improved effector functions and multi-targeting capabilities.
  • Novel effector functions, including reactive oxygen species generation for inflammation or bacterial killing, have been identified.
  • Immunoglobulin A antibodies are emerging as a new class of therapeutic agents.

Conclusions:

  • Engineered antibodies are progressing into clinical trials with promising results.
  • The development of novel effector mechanisms broadens the therapeutic potential of antibodies.
  • The inclusion of immunoglobulin A expands the landscape of antibody-based therapies.